Provided are a composition including Stellera chamaejasme extract for treating wound, a method of treating wound of a subject, a cosmetic composition for wound improving, skin wrinkle improving, or skin anti-aging, and a method of cosmeticizing for wound improving, skin wrinkle improving, or skin anti-aging.

Masking particles which comprise a drug-containing particle containing a drug, an acid, and a carbonate, the drug-containing particle being coated with a coating layer containing a water-insoluble polymer sufficiently suppress drug release in the oral cavity and pharynx, rapidly release a drug after swallowing, and easily control the release suppression time of a drug. The acid may be at least one organic acid. The carbonate may be at least one water-soluble carbonate. Oral pharmaceutical compositions include tablets, granules, fine granules, powders.

The present disclosure generally relates to a composition matter and a method for cancer treatment comprising albumin (alb) coated tannic acid-Fe nanoparticles (NPs) with a therapeutic compound, and one or more diluents, excipients or carriers. In particular, the present invention provides a treatment by enhancing antitumor immunity using tannic acid-based nanoparticles containing a therapeutic cancer treatment that can induce immunogenic cell death (ICD). The method disclosed herein provides a potential solution to the immunotoxicity accompanying the ICD cancer immunotherapy by intratumoral or intravenous administration of a nanocapsule formulation of carfilzomib (CFZ), an ICD-inducing proteasome inhibitor, using interfacial supramolecular assembly of tannic acid (TA) and iron, supplemented with albumin coating for better metabolic stability.

This invention relates to a product that is formulated with the goal of protecting the human body from the harmful effects of ionizing and non-ionizing electromagnetic radiations. Examples of ionizing radiations addressed by this invention include, but are not limited to, gamma- and X-rays. Non-ionizing electromagnetic radiations include, but are not limited to, radio waves such as those used for mobile telecommunication comprising the fifth generation technology standard for cellular networks, also known as 5G.

This invention is based on biological quantum entanglement occurring at the level of DNA repair genes of commensal microorganisms (cyanobacteria) that are extremely resistant to the killing effects of electromagnetic radiations. The DNA repair genes that are described in this invention are those involved with the repair of DNA lesions observed as consequence of exposure to ionizing and non-ionizing radiations. Expression of these genes in cyanobacteria is induced by their culture in a medium of carbonated mineral water naturally containing the radioactive isotopes .sup.228U and its product of decay, .sup.226Ra. Superluminal particles emitted by these isotopes are the source of Cherenkov radiation that, in turn, stimulates photosynthesis in the cyanobacteria. Photosynthesis is a phenomenon based on quantum entanglement; simultaneous induction of DNA repair genes and photosynthesis, enables entanglement between the DNA repair genes of cyanobacteria and those of commensal microorganisms that are part of the human microbiota and are cultured, under the form of a proprietary probiotic blend described in detail in this document, together with cyanobacteria in the culture medium. The culture medium, in addition to naturally radioactive water, is formulated to enhance horizontal gene transfer thanks to the presence of silica from Equisetum arvense. Radio-resistant edible cyanobacteria (that are classified as prebiotics), and entangled probiotic microorganisms are encapsulated for human consumption after a conventional process of freeze-drying. Transfer of resistance to the harmful effects of electromagnetic radiations to human cells is achieved through a Lactococcus phage-encoded protein, ORF252, that is the evolutionary precursor of human proteins involved in DNA repair and cancer protection. An application of this invention consists in its use for protecting normal (healthy) human cells subjected to radiation therapy, at the same time maximizing the therapeutic effects on radiation therapy. This document also comprises the original manufacturing methods of the pre-probiotic formula briefly described above.

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

The disclosed invention relates to a low-dose celecoxib oral formulation, and a preparation method therefor, which is characterized in that the strength of the formulation is 60-90% of the original strength of the commercial celecoxib product, and the celecoxib formulation with such reduced strength is bioequivalent to the commercial celecoxib product. The celecoxib formulation can be used for the treatment of mild to moderate pain and mild to moderate chronic pain.

A solid pharmaceutical composition comprising a quinazoline derivative or a medicinal salt thereof, and a preparation method therefor. Specifically, provided is a solid pharmaceutical composition comprising N.sup.6-(1-acryloylpiperidin-4-yl)-N.sup.4-(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine or a medicinal salt thereof, and a preparation method therefor and use thereof.

##STR00001##

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

A composition having nanoparticles having lipids; a polysaccharide coating, an active agent and iron oxide. The active agent can be ciprofloxacin or fluocinolone. A method of treatment of ear disease or ear infection including the administration of a pharmaceutical formulation comprising nanoparticles and magnetically pushing or pulling the nanoparticles to a treatment site.

The invention relates to a pharmaceutical composition containing alginate oligosaccharide diacid with formula (IV) or a pharmaceutically acceptable salt thereof, which can be used for preparing medicaments for treating Alzheimer's disease, Parkinson's disease, inflammation, pain, diabetes or vascular dementia.

##STR00001##